WO2025237353 - ANTI-GIPR ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/237353
Publication Date
20.11.2025
International Application No.
PCT/CN2025/094991
International Filing Date
15.05.2025
Title **
[English]
ANTI-GIPR ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
[French]
ANTICORPS ANTI-GIPR OU FRAGMENT DE LIAISON À L'ANTIGÈNE DE CELUI-CI ET SON UTILISATION
[Chinese]
一种抗GIPR抗体或其抗原结合片段及用途
Applicants **
SALUBRIS (CHENGDU) BIOTECH CO., LTD.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
SALUBRIS (SUZHOU) PHARMACEUTICALS CO., LTD.
Inventors
YE, Junmin
MOU, Zongchun
LIU, Xiaohong
PENG, Xiaolun
XIANG, Shuzhou
ZHANG, Peng
ZENG, Yu
XIONG, Xiaolin
Priority Data
202410606256.0
15.05.2024
CN
202510000757.9
02.01.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1902 | |
| EPO | Filing, Examination, Granting | 13332 | |
| Japan | Filing, Examination, Granting | 2276 | |
| South Korea | Filing, Examination, Granting | 2304 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,554
Contact Us
Abstract[English]
Provided is an anti-GIPR antibody or an antigen-binding fragment thereof, and further provided are a polynucleotide encoding the antibody, a vector and host cell for expressing the antibody, a pharmaceutical composition containing the antibody, and a method and the pharmaceutical use of the antibody in the treatment of GIPR-related diseases.[French]
L'invention concerne un anticorps anti-GIPR ou un fragment de liaison à l'antigène de celui-ci, et concerne en outre un polynucléotide codant pour l'anticorps, un vecteur et une cellule hôte pour exprimer l'anticorps, une composition pharmaceutique contenant l'anticorps, et un procédé et l'utilisation pharmaceutique de l'anticorps dans le traitement de maladies associées à GIPR.[Chinese]
提供了一种抗GIPR抗体或其抗原结合片段，还提供了编码所述抗体的多核苷酸，用于表达所述抗体的载体和宿主细胞，包含所述抗体的药物组合物，以及所述抗体用于治疗与GIPR相关的疾病的方法和制药用途。